Hyperuricemia Drugs
Middle East · 1 shared keyword
Updated
Reviewed by Vidhi Upadhyay
Middle East Gout Treatment Market Industry Trends and Forecast to 2034: Segmented by (Drug Class, Type, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$208.8 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $171.7 Mn | — | — |
| 2025 (base) | $186.7 Mn | +$14.9 Mn | — |
| 2026 (forecast) | $202.9 Mn | +$16.2 Mn | +8.7% |
| 2027 (forecast) | $220.6 Mn | +$17.7 Mn | +18.2% |
| 2028 (forecast) | $239.8 Mn | +$19.2 Mn | +28.4% |
| 2029 (forecast) | $260.6 Mn | +$20.9 Mn | +39.6% |
| 2030 (forecast) | $283.3 Mn | +$22.7 Mn | +51.8% |
| 2031 (forecast) | $308.0 Mn | +$24.6 Mn | +65% |
| 2032 (forecast) | $334.8 Mn | +$26.8 Mn | +79.3% |
| 2033 (forecast) | $363.9 Mn | +$29.1 Mn | +94.9% |
| 2034 (forecast) | $395.5 Mn | +$31.7 Mn | +111.9% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $186.7 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $395.5 Mn placeholder estimate |
| Growth (CAGR), 2025–2034 | 8.7% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Drug class, type and end user (see all) |
| Key players | Horizon Therapeutics (Amgen), Takeda Pharmaceutical Company Ltd, Novartis AG, Teva Pharmaceutical, Shanton Pharma (see all) |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Gout treatments lower uric acid and control painful flares caused by crystals in the joints.
Key segments of the gout Treatment market include drug class (Xanthine Oxidase Inhibitors, Uricosurics and Colchicine) and type (Acute Gout and Chronic Gout).
Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the gout Treatment market. Wider insurance coverage and more doctors trained in obesity care are adding to demand.
Oral formulations, combination therapies and use in heart, kidney and liver disease open new growth paths for the gout Treatment market, especially in fast-growing emerging economies.
High treatment prices, limited reimbursement, supply shortages and side effects that lead some patients to stop treatment hold back the gout Treatment market. Long-term safety data and lifestyle support are still needed for many patients.
The gout Treatment market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
In some of the countries we cover here, medicines are approved by SFDA (Saudi Arabia)[1] and EDE (UAE)[2]. How care is paid for in some of these countries: free public care and CHI-regulated insurance (Saudi Arabia)[3] and mandatory health insurance (UAE)[4].
[1] Saudi Food and Drug Authority. Checked 14 Nov 2026.
[2] Emirates Drug Establishment. Checked 14 Nov 2026.
[3] Council of Health Insurance. Checked 14 Nov 2026.
[4] Ministry of Human Resources and Emiratisation. Checked 14 Nov 2026.
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for gout Treatment. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Middle East.
What doctors and scientists are doing in Gout Treatment right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
Middle East · 1 shared keyword
Middle East · 1 shared keyword
Middle East · 1 shared keyword
Middle East · 1 shared keyword
Middle East · 1 shared keyword
Middle East · 1 shared keyword
OTC & Nutraceuticals · Middle East
Medical Devices · Middle East
Medical Devices · Middle East
Public Health · Global